Related references
Note: Only part of the references are listed.Relapse prevention study of paliperidone eltended-release tablets in Chinese patients with schizophrenia
Qing Rui et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2014)
Risk of symptom recurrence with medication discontinuation in first-episode psychosis: A systematic review
Robert B. Zipursky et al.
SCHIZOPHRENIA RESEARCH (2014)
Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options
Pierre Chue et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2014)
Body mass index and quality of life among outpatients with schizophrenia in Japan
Norio Sugawara et al.
BMC PSYCHIATRY (2013)
Is the ongoing use of placebo in relapse-prevention clinical trials in schizophrenia justified?
Robin Emsley et al.
SCHIZOPHRENIA RESEARCH (2013)
Ethical Issues of Placebo-Controlled Studies in Depression and a Randomized Withdrawal Trial in Japan Case Study in the Ethics of Mental Health Research
Shimon Tashiro et al.
JOURNAL OF NERVOUS AND MENTAL DISEASE (2012)
Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients
Norio Yasui-Furukori et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2012)
Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia
Robin Emsley et al.
SCHIZOPHRENIA RESEARCH (2012)
Attitudes of patients with schizophrenia and depression to psychiatric research: a study in seven European countries
Ingo Schaefer et al.
SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY (2011)
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
Marc De Hert et al.
WORLD PSYCHIATRY (2011)
Guidelines for rating Global Assessment of Functioning (GAF)
I. H. Monrad Aas
ANNALS OF GENERAL PSYCHIATRY (2011)
Prevalence of metabolic syndrome among patients with schizophrenia in Japan
Norio Sugawara et al.
SCHIZOPHRENIA RESEARCH (2010)
Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs - A meta-analysis
G Kemmler et al.
ARCHIVES OF GENERAL PSYCHIATRY (2005)
Placebo or active control trials of antipsychotic drugs?
WW Fleischhacker et al.
ARCHIVES OF GENERAL PSYCHIATRY (2003)
Attitudes of patients with schizophrenia toward placebo-controlled clinical trials
M Hummer et al.
JOURNAL OF CLINICAL PSYCHIATRY (2003)
The declaration of Helsinki and clinical trials: A focus on placebo-controlled trials in schizophrenia
WT Carpenter et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
Feasibility of placebo-controlled clinical trials of antipsychotic compounds in Europe
WW Fleischhacker et al.
PSYCHOPHARMACOLOGY (2002)
Patient and psychiatrist ratings of hypothetical schizophrenia research protocols: Assessment of harm potential and factors influencing participation decisions
LW Roberts et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
Therapeutic effects of bromperidol on the five dimensions of schizophrenic symptoms
N Yasui-Furukori et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2002)
Subject selection for the placebo- and comparator-controlled trials of neuroleptics in schizophrenia
P Mohr et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2000)
Share Paper
